APO Research
Talk to an analyst

APO RESEARCH · REPORT

Epistaxis

Compare research editions
View pricing & licenses

Selected research

Industry Research

Epistaxis Industry Research Report 2026

22 December 2025150 pages

Choose your research edition.

Industry ResearchEpistaxis Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Epistaxis Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Epistaxis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Epistaxis Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Epistaxis Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Epistaxis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Epistaxis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Epistaxis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Epistaxis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Epistaxis include Teva Pharmaceutical Industries Ltd., Sanofi, Johnson & Johnson, Novartis AG, Mylan N.V., Eli Lilly and Company, Pfizer Inc, GlaxoSmithKline plc and Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Epistaxis market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Epistaxis Market by Company

Teva Pharmaceutical Industries Ltd.

Sanofi

Johnson & Johnson

Novartis AG

Mylan N.V.

Eli Lilly and Company

Pfizer Inc

GlaxoSmithKline plc

Bayer AG

Amgen Inc

AbbVie Inc

AstraZeneca

Smith & Nephew

Merck & Co., Inc

Medline

Lupin

King Pharmaceuticals, Inc

Hikma Pharmaceuticals PLC

Gilead Sciences, Inc

F. Hoffmann-La Roche Ltd

Dr. Reddy’s Laboratories Ltd

Ciron Drugs

Bristol-Myers Squibb Pharma Company

Boehringer Ingelheim International GmbH

Allergan

Epistaxis Segment by Type

Cauterizing Agents

Vasoconstrictors

Anesthetics

Antibiotic Ointments

Epistaxis Segment by Application

Pediatric

Adult

Epistaxis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epistaxis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Epistaxis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epistaxis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Epistaxis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Epistaxis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Epistaxis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Epistaxis Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Epistaxis Sales (k units) of Manufacturers (2021-2026) Table 7. Global Epistaxis Sales Market Share by Manufacturers (2021-2026) Table 8. Global Epistaxis Revenue of Manufacturers (2021-2026) Table 9. Global Epistaxis Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Epistaxis Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Epistaxis Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Epistaxis, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Epistaxis, Product Type & Application Table 14. Global Epistaxis Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Epistaxis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceutical Industries Ltd. Company Information Table 19. Teva Pharmaceutical Industries Ltd. Business Overview Table 20. Teva Pharmaceutical Industries Ltd. Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceutical Industries Ltd. Epistaxis Product Portfolio Table 22. Teva Pharmaceutical Industries Ltd. Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Sanofi Epistaxis Product Portfolio Table 27. Sanofi Recent Developments Table 28. Johnson & Johnson Company Information Table 29. Johnson & Johnson Business Overview Table 30. Johnson & Johnson Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Johnson & Johnson Epistaxis Product Portfolio Table 32. Johnson & Johnson Recent Developments Table 33. Novartis AG Company Information Table 34. Novartis AG Business Overview Table 35. Novartis AG Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Novartis AG Epistaxis Product Portfolio Table 37. Novartis AG Recent Developments Table 38. Mylan N.V. Company Information Table 39. Mylan N.V. Business Overview Table 40. Mylan N.V. Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Mylan N.V. Epistaxis Product Portfolio Table 42. Mylan N.V. Recent Developments Table 43. Eli Lilly and Company Company Information Table 44. Eli Lilly and Company Business Overview Table 45. Eli Lilly and Company Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Eli Lilly and Company Epistaxis Product Portfolio Table 47. Eli Lilly and Company Recent Developments Table 48. Pfizer Inc Company Information Table 49. Pfizer Inc Business Overview Table 50. Pfizer Inc Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Pfizer Inc Epistaxis Product Portfolio Table 52. Pfizer Inc Recent Developments Table 53. GlaxoSmithKline plc Company Information Table 54. GlaxoSmithKline plc Business Overview Table 55. GlaxoSmithKline plc Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. GlaxoSmithKline plc Epistaxis Product Portfolio Table 57. GlaxoSmithKline plc Recent Developments Table 58. Bayer AG Company Information Table 59. Bayer AG Business Overview Table 60. Bayer AG Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Bayer AG Epistaxis Product Portfolio Table 62. Bayer AG Recent Developments Table 63. Amgen Inc Company Information Table 64. Amgen Inc Business Overview Table 65. Amgen Inc Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Amgen Inc Epistaxis Product Portfolio Table 67. Amgen Inc Recent Developments Table 68. AbbVie Inc Company Information Table 69. AbbVie Inc Business Overview Table 70. AbbVie Inc Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. AbbVie Inc Epistaxis Product Portfolio Table 72. AbbVie Inc Recent Developments Table 73. AstraZeneca Company Information Table 74. AstraZeneca Business Overview Table 75. AstraZeneca Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. AstraZeneca Epistaxis Product Portfolio Table 77. AstraZeneca Recent Developments Table 78. Smith & Nephew Company Information Table 79. Smith & Nephew Business Overview Table 80. Smith & Nephew Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Smith & Nephew Epistaxis Product Portfolio Table 82. Smith & Nephew Recent Developments Table 83. Merck & Co., Inc Company Information Table 84. Merck & Co., Inc Business Overview Table 85. Merck & Co., Inc Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck & Co., Inc Epistaxis Product Portfolio Table 87. Merck & Co., Inc Recent Developments Table 88. Medline Company Information Table 89. Medline Business Overview Table 90. Medline Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Medline Epistaxis Product Portfolio Table 92. Medline Recent Developments Table 93. Lupin Company Information Table 94. Lupin Business Overview Table 95. Lupin Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Lupin Epistaxis Product Portfolio Table 97. Lupin Recent Developments Table 98. King Pharmaceuticals, Inc Company Information Table 99. King Pharmaceuticals, Inc Business Overview Table 100. King Pharmaceuticals, Inc Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. King Pharmaceuticals, Inc Epistaxis Product Portfolio Table 102. King Pharmaceuticals, Inc Recent Developments Table 103. Hikma Pharmaceuticals PLC Company Information Table 104. Hikma Pharmaceuticals PLC Business Overview Table 105. Hikma Pharmaceuticals PLC Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Hikma Pharmaceuticals PLC Epistaxis Product Portfolio Table 107. Hikma Pharmaceuticals PLC Recent Developments Table 108. Gilead Sciences, Inc Company Information Table 109. Gilead Sciences, Inc Business Overview Table 110. Gilead Sciences, Inc Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Gilead Sciences, Inc Epistaxis Product Portfolio Table 112. Gilead Sciences, Inc Recent Developments Table 113. F. Hoffmann-La Roche Ltd Company Information Table 114. F. Hoffmann-La Roche Ltd Business Overview Table 115. F. Hoffmann-La Roche Ltd Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. F. Hoffmann-La Roche Ltd Epistaxis Product Portfolio Table 117. F. Hoffmann-La Roche Ltd Recent Developments Table 118. Dr. Reddy’s Laboratories Ltd Company Information Table 119. Dr. Reddy’s Laboratories Ltd Business Overview Table 120. Dr. Reddy’s Laboratories Ltd Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Dr. Reddy’s Laboratories Ltd Epistaxis Product Portfolio Table 122. Dr. Reddy’s Laboratories Ltd Recent Developments Table 123. Ciron Drugs Company Information Table 124. Ciron Drugs Business Overview Table 125. Ciron Drugs Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Ciron Drugs Epistaxis Product Portfolio Table 127. Ciron Drugs Recent Developments Table 128. Bristol-Myers Squibb Pharma Company Company Information Table 129. Bristol-Myers Squibb Pharma Company Business Overview Table 130. Bristol-Myers Squibb Pharma Company Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Bristol-Myers Squibb Pharma Company Epistaxis Product Portfolio Table 132. Bristol-Myers Squibb Pharma Company Recent Developments Table 133. Boehringer Ingelheim International GmbH Company Information Table 134. Boehringer Ingelheim International GmbH Business Overview Table 135. Boehringer Ingelheim International GmbH Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Boehringer Ingelheim International GmbH Epistaxis Product Portfolio Table 137. Boehringer Ingelheim International GmbH Recent Developments Table 138. Allergan Company Information Table 139. Allergan Business Overview Table 140. Allergan Epistaxis Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Allergan Epistaxis Product Portfolio Table 142. Allergan Recent Developments Table 143. Global Epistaxis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 144. Global Epistaxis Sales by Region (2021-2026) & (k units) Table 145. Global Epistaxis Sales Market Share by Region (2021-2026) Table 146. Global Epistaxis Sales by Region (2027-2032) & (k units) Table 147. Global Epistaxis Sales Market Share by Region (2027-2032) Table 148. Global Epistaxis Revenue by Region (2021-2026) & (US$ Million) Table 149. Global Epistaxis Revenue Market Share by Region (2021-2026) Table 150. Global Epistaxis Revenue by Region (2027-2032) & (US$ Million) Table 151. Global Epistaxis Revenue Market Share by Region (2027-2032) Table 152. North America Epistaxis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. North America Epistaxis Sales by Country (2021-2026) & (k units) Table 154. North America Epistaxis Sales by Country (2027-2032) & (k units) Table 155. North America Epistaxis Revenue by Country (2021-2026) & (US$ Million) Table 156. North America Epistaxis Revenue by Country (2027-2032) & (US$ Million) Table 157. Europe Epistaxis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Europe Epistaxis Sales by Country (2021-2026) & (k units) Table 159. Europe Epistaxis Sales by Country (2027-2032) & (k units) Table 160. Europe Epistaxis Revenue by Country (2021-2026) & (US$ Million) Table 161. Europe Epistaxis Revenue by Country (2027-2032) & (US$ Million) Table 162. Asia Pacific Epistaxis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Asia Pacific Epistaxis Sales by Country (2021-2026) & (k units) Table 164. Asia Pacific Epistaxis Sales by Country (2027-2032) & (k units) Table 165. Asia Pacific Epistaxis Revenue by Country (2021-2026) & (US$ Million) Table 166. Asia Pacific Epistaxis Revenue by Country (2027-2032) & (US$ Million) Table 167. South America Epistaxis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. South America Epistaxis Sales by Country (2021-2026) & (k units) Table 169. South America Epistaxis Sales by Country (2027-2032) & (k units) Table 170. South America Epistaxis Revenue by Country (2021-2026) & (US$ Million) Table 171. South America Epistaxis Revenue by Country (2027-2032) & (US$ Million) Table 172. Middle East and Africa Epistaxis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. Middle East and Africa Epistaxis Sales by Country (2021-2026) & (k units) Table 174. Middle East and Africa Epistaxis Sales by Country (2027-2032) & (k units) Table 175. Middle East and Africa Epistaxis Revenue by Country (2021-2026) & (US$ Million) Table 176. Middle East and Africa Epistaxis Revenue by Country (2027-2032) & (US$ Million) Table 177. Global Epistaxis Sales by Type (2021-2026) & (k units) Table 178. Global Epistaxis Sales by Type (2027-2032) & (k units) Table 179. Global Epistaxis Sales Market Share by Type (2021-2026) Table 180. Global Epistaxis Sales Market Share by Type (2027-2032) Table 181. Global Epistaxis Revenue by Type (2021-2026) & (US$ Million) Table 182. Global Epistaxis Revenue by Type (2027-2032) & (US$ Million) Table 183. Global Epistaxis Revenue Market Share by Type (2021-2026) Table 184. Global Epistaxis Revenue Market Share by Type (2027-2032) Table 185. Global Epistaxis Price by Type (2021-2026) & (US$/unit) Table 186. Global Epistaxis Price by Type (2027-2032) & (US$/unit) Table 187. Global Epistaxis Sales by Application (2021-2026) & (k units) Table 188. Global Epistaxis Sales by Application (2027-2032) & (k units) Table 189. Global Epistaxis Sales Market Share by Application (2021-2026) Table 190. Global Epistaxis Sales Market Share by Application (2027-2032) Table 191. Global Epistaxis Revenue by Application (2021-2026) & (US$ Million) Table 192. Global Epistaxis Revenue by Application (2027-2032) & (US$ Million) Table 193. Global Epistaxis Revenue Market Share by Application (2021-2026) Table 194. Global Epistaxis Revenue Market Share by Application (2027-2032) Table 195. Global Epistaxis Price by Application (2021-2026) & (US$/unit) Table 196. Global Epistaxis Price by Application (2027-2032) & (US$/unit) Table 197. Key Raw Materials Table 198. Raw Materials Key Suppliers Table 199. Epistaxis Distributors List Table 200. Epistaxis Customers List Table 201. Epistaxis Industry Trends Table 202. Epistaxis Industry Drivers Table 203. Epistaxis Industry Restraints Table 204. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Epistaxis Product Image Figure 5. Global Epistaxis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Epistaxis Market Size (2021-2032) & (US$ Million) Figure 7. Global Epistaxis Sales (2021-2032) & (k units) Figure 8. Global Epistaxis Average Price (US$/unit) & (2021-2032) Figure 9. Cauterizing Agents Product Image Figure 10. Vasoconstrictors Product Image Figure 11. Anesthetics Product Image Figure 12. Antibiotic Ointments Product Image Figure 13. Pediatric Product Image Figure 14. Adult Product Image Figure 15. Global Epistaxis Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Epistaxis, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Epistaxis Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Epistaxis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Epistaxis Sales by Region in 2025 Figure 21. Global Epistaxis Revenue by Region in 2025 Figure 22. North America Epistaxis Market Size by Country in 2025 Figure 23. North America Epistaxis Sales Market Share by Country (2021-2032) Figure 24. North America Epistaxis Revenue Market Share by Country (2021-2032) Figure 25. United States Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Epistaxis Market Size by Country in 2025 Figure 29. Europe Epistaxis Sales Market Share by Country (2021-2032) Figure 30. Europe Epistaxis Revenue Market Share by Country (2021-2032) Figure 31. Germany Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Epistaxis Market Size by Country in 2025 Figure 42. Asia Pacific Epistaxis Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Epistaxis Revenue Market Share by Country (2021-2032) Figure 44. China Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Epistaxis Market Size by Country in 2025 Figure 53. South America Epistaxis Sales Market Share by Country (2021-2032) Figure 54. South America Epistaxis Revenue Market Share by Country (2021-2032) Figure 55. Brazil Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Epistaxis Market Size by Country in 2025 Figure 59. Middle East and Africa Epistaxis Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Epistaxis Revenue Market Share by Country (2021-2032) Figure 61. Egypt Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Epistaxis Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Epistaxis Sales Market Share by Type (2021-2032) Figure 67. Global Epistaxis Revenue Market Share by Type (2021-2032) Figure 68. Global Epistaxis Price (US$/unit) by Type (2021-2032) Figure 69. Global Epistaxis Sales Market Share by Application (2021-2032) Figure 70. Global Epistaxis Revenue Market Share by Application (2021-2032) Figure 71. Global Epistaxis Price (US$/unit) by Application (2021-2032) Figure 72. Epistaxis Value Chain Figure 73. Epistaxis Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Epistaxis Industry Opportunities and Challenges

Scope & coverage.

Types
  • Cauterizing Agents
  • Vasoconstrictors
  • Anesthetics
  • Antibiotic Ointments
Applications
  • Pediatric
  • Adult
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Johnson & Johnson
  • Novartis AG
  • Mylan N.V.
  • Eli Lilly and Company
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Bayer AG
  • Amgen Inc
  • AbbVie Inc
  • AstraZeneca
  • Smith & Nephew
  • Merck & Co., Inc
  • Medline
  • Lupin
  • King Pharmaceuticals, Inc
  • Hikma Pharmaceuticals PLC
  • Gilead Sciences, Inc
  • F. Hoffmann-La Roche Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Ciron Drugs
  • Bristol-Myers Squibb Pharma Company
  • Boehringer Ingelheim International GmbH
  • Allergan

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Epistaxis Market Size (2021-2032)
  4. 2.2.2 Global Epistaxis Sales (2021-2032)
  5. 2.2.3 Global Epistaxis Market Average Price (2021-2032)
  6. 2.3 Epistaxis by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Cauterizing Agents
  9. 2.3.3 Vasoconstrictors
  10. 2.3.4 Anesthetics
  11. 2.3.5 Antibiotic Ointments
  12. 2.4 Epistaxis by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Pediatric
  15. 2.4.3 Adult
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Epistaxis Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Epistaxis Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Epistaxis Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Epistaxis Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Epistaxis Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Epistaxis, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Epistaxis, Product Type & Application
  8. 3.8 Global Manufacturers of Epistaxis, Established Date
  9. 3.9 Global Epistaxis Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical Industries Ltd.
  2. 4.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 4.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 4.1.3 Teva Pharmaceutical Industries Ltd. Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Industries Ltd. Epistaxis Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Epistaxis Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Johnson & Johnson
  14. 4.3.1 Johnson & Johnson Company Information
  15. 4.3.2 Johnson & Johnson Business Overview
  16. 4.3.3 Johnson & Johnson Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Johnson & Johnson Epistaxis Product Portfolio
  18. 4.3.5 Johnson & Johnson Recent Developments
  19. 4.4 Novartis AG
  20. 4.4.1 Novartis AG Company Information
  21. 4.4.2 Novartis AG Business Overview
  22. 4.4.3 Novartis AG Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis AG Epistaxis Product Portfolio
  24. 4.4.5 Novartis AG Recent Developments
  25. 4.5 Mylan N.V.
  26. 4.5.1 Mylan N.V. Company Information
  27. 4.5.2 Mylan N.V. Business Overview
  28. 4.5.3 Mylan N.V. Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mylan N.V. Epistaxis Product Portfolio
  30. 4.5.5 Mylan N.V. Recent Developments
  31. 4.6 Eli Lilly and Company
  32. 4.6.1 Eli Lilly and Company Company Information
  33. 4.6.2 Eli Lilly and Company Business Overview
  34. 4.6.3 Eli Lilly and Company Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Eli Lilly and Company Epistaxis Product Portfolio
  36. 4.6.5 Eli Lilly and Company Recent Developments
  37. 4.7 Pfizer Inc
  38. 4.7.1 Pfizer Inc Company Information
  39. 4.7.2 Pfizer Inc Business Overview
  40. 4.7.3 Pfizer Inc Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Inc Epistaxis Product Portfolio
  42. 4.7.5 Pfizer Inc Recent Developments
  43. 4.8 GlaxoSmithKline plc
  44. 4.8.1 GlaxoSmithKline plc Company Information
  45. 4.8.2 GlaxoSmithKline plc Business Overview
  46. 4.8.3 GlaxoSmithKline plc Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 GlaxoSmithKline plc Epistaxis Product Portfolio
  48. 4.8.5 GlaxoSmithKline plc Recent Developments
  49. 4.9 Bayer AG
  50. 4.9.1 Bayer AG Company Information
  51. 4.9.2 Bayer AG Business Overview
  52. 4.9.3 Bayer AG Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Bayer AG Epistaxis Product Portfolio
  54. 4.9.5 Bayer AG Recent Developments
  55. 4.10 Amgen Inc
  56. 4.10.1 Amgen Inc Company Information
  57. 4.10.2 Amgen Inc Business Overview
  58. 4.10.3 Amgen Inc Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Amgen Inc Epistaxis Product Portfolio
  60. 4.10.5 Amgen Inc Recent Developments
  61. 4.11 AbbVie Inc
  62. 4.11.1 AbbVie Inc Company Information
  63. 4.11.2 AbbVie Inc Business Overview
  64. 4.11.3 AbbVie Inc Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 AbbVie Inc Epistaxis Product Portfolio
  66. 4.11.5 AbbVie Inc Recent Developments
  67. 4.12 AstraZeneca
  68. 4.12.1 AstraZeneca Company Information
  69. 4.12.2 AstraZeneca Business Overview
  70. 4.12.3 AstraZeneca Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 AstraZeneca Epistaxis Product Portfolio
  72. 4.12.5 AstraZeneca Recent Developments
  73. 4.13 Smith & Nephew
  74. 4.13.1 Smith & Nephew Company Information
  75. 4.13.2 Smith & Nephew Business Overview
  76. 4.13.3 Smith & Nephew Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Smith & Nephew Epistaxis Product Portfolio
  78. 4.13.5 Smith & Nephew Recent Developments
  79. 4.14 Merck & Co., Inc
  80. 4.14.1 Merck & Co., Inc Company Information
  81. 4.14.2 Merck & Co., Inc Business Overview
  82. 4.14.3 Merck & Co., Inc Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Merck & Co., Inc Epistaxis Product Portfolio
  84. 4.14.5 Merck & Co., Inc Recent Developments
  85. 4.15 Medline
  86. 4.15.1 Medline Company Information
  87. 4.15.2 Medline Business Overview
  88. 4.15.3 Medline Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Medline Epistaxis Product Portfolio
  90. 4.15.5 Medline Recent Developments
  91. 4.16 Lupin
  92. 4.16.1 Lupin Company Information
  93. 4.16.2 Lupin Business Overview
  94. 4.16.3 Lupin Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Lupin Epistaxis Product Portfolio
  96. 4.16.5 Lupin Recent Developments
  97. 4.17 King Pharmaceuticals, Inc
  98. 4.17.1 King Pharmaceuticals, Inc Company Information
  99. 4.17.2 King Pharmaceuticals, Inc Business Overview
  100. 4.17.3 King Pharmaceuticals, Inc Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 King Pharmaceuticals, Inc Epistaxis Product Portfolio
  102. 4.17.5 King Pharmaceuticals, Inc Recent Developments
  103. 4.18 Hikma Pharmaceuticals PLC
  104. 4.18.1 Hikma Pharmaceuticals PLC Company Information
  105. 4.18.2 Hikma Pharmaceuticals PLC Business Overview
  106. 4.18.3 Hikma Pharmaceuticals PLC Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Hikma Pharmaceuticals PLC Epistaxis Product Portfolio
  108. 4.18.5 Hikma Pharmaceuticals PLC Recent Developments
  109. 4.19 Gilead Sciences, Inc
  110. 4.19.1 Gilead Sciences, Inc Company Information
  111. 4.19.2 Gilead Sciences, Inc Business Overview
  112. 4.19.3 Gilead Sciences, Inc Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Gilead Sciences, Inc Epistaxis Product Portfolio
  114. 4.19.5 Gilead Sciences, Inc Recent Developments
  115. 4.20 F. Hoffmann-La Roche Ltd
  116. 4.20.1 F. Hoffmann-La Roche Ltd Company Information
  117. 4.20.2 F. Hoffmann-La Roche Ltd Business Overview
  118. 4.20.3 F. Hoffmann-La Roche Ltd Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 F. Hoffmann-La Roche Ltd Epistaxis Product Portfolio
  120. 4.20.5 F. Hoffmann-La Roche Ltd Recent Developments
  121. 4.21 Dr. Reddy’s Laboratories Ltd
  122. 4.21.1 Dr. Reddy’s Laboratories Ltd Company Information
  123. 4.21.2 Dr. Reddy’s Laboratories Ltd Business Overview
  124. 4.21.3 Dr. Reddy’s Laboratories Ltd Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Dr. Reddy’s Laboratories Ltd Epistaxis Product Portfolio
  126. 4.21.5 Dr. Reddy’s Laboratories Ltd Recent Developments
  127. 4.22 Ciron Drugs
  128. 4.22.1 Ciron Drugs Company Information
  129. 4.22.2 Ciron Drugs Business Overview
  130. 4.22.3 Ciron Drugs Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Ciron Drugs Epistaxis Product Portfolio
  132. 4.22.5 Ciron Drugs Recent Developments
  133. 4.23 Bristol-Myers Squibb Pharma Company
  134. 4.23.1 Bristol-Myers Squibb Pharma Company Company Information
  135. 4.23.2 Bristol-Myers Squibb Pharma Company Business Overview
  136. 4.23.3 Bristol-Myers Squibb Pharma Company Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Bristol-Myers Squibb Pharma Company Epistaxis Product Portfolio
  138. 4.23.5 Bristol-Myers Squibb Pharma Company Recent Developments
  139. 4.24 Boehringer Ingelheim International GmbH
  140. 4.24.1 Boehringer Ingelheim International GmbH Company Information
  141. 4.24.2 Boehringer Ingelheim International GmbH Business Overview
  142. 4.24.3 Boehringer Ingelheim International GmbH Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Boehringer Ingelheim International GmbH Epistaxis Product Portfolio
  144. 4.24.5 Boehringer Ingelheim International GmbH Recent Developments
  145. 4.25 Allergan
  146. 4.25.1 Allergan Company Information
  147. 4.25.2 Allergan Business Overview
  148. 4.25.3 Allergan Epistaxis Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Allergan Epistaxis Product Portfolio
  150. 4.25.5 Allergan Recent Developments
5 Global Epistaxis Market Scenario by Region
  1. 5.1 Global Epistaxis Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Epistaxis Sales by Region: 2021-2032
  3. 5.2.1 Global Epistaxis Sales by Region: 2021-2026
  4. 5.2.2 Global Epistaxis Sales by Region: 2027-2032
  5. 5.3 Global Epistaxis Revenue by Region: 2021-2032
  6. 5.3.1 Global Epistaxis Revenue by Region: 2021-2026
  7. 5.3.2 Global Epistaxis Revenue by Region: 2027-2032
  8. 5.4 North America Epistaxis Market Facts & Figures by Country
  9. 5.4.1 North America Epistaxis Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Epistaxis Sales by Country (2021-2032)
  11. 5.4.3 North America Epistaxis Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Epistaxis Market Facts & Figures by Country
  16. 5.5.1 Europe Epistaxis Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Epistaxis Sales by Country (2021-2032)
  18. 5.5.3 Europe Epistaxis Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Epistaxis Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Epistaxis Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Epistaxis Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Epistaxis Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Epistaxis Market Facts & Figures by Country
  41. 5.7.1 South America Epistaxis Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Epistaxis Sales by Country (2021-2032)
  43. 5.7.3 South America Epistaxis Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Epistaxis Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Epistaxis Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Epistaxis Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Epistaxis Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Epistaxis Sales by Type (2021-2032)
  2. 6.1.1 Global Epistaxis Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Epistaxis Sales Market Share by Type (2021-2032)
  4. 6.2 Global Epistaxis Revenue by Type (2021-2032)
  5. 6.2.1 Global Epistaxis Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Epistaxis Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Epistaxis Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Epistaxis Sales by Application (2021-2032)
  2. 7.1.1 Global Epistaxis Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Epistaxis Sales Market Share by Application (2021-2032)
  4. 7.2 Global Epistaxis Revenue by Application (2021-2032)
  5. 7.2.1 Global Epistaxis Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Epistaxis Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Epistaxis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Epistaxis Value Chain Analysis
  2. 8.1.1 Epistaxis Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Epistaxis Production Mode & Process
  5. 8.2 Epistaxis Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Epistaxis Distributors
  8. 8.2.3 Epistaxis Customers
9 Global Epistaxis Analyzing Market Dynamics
  1. 9.1 Epistaxis Industry Trends
  2. 9.2 Epistaxis Industry Drivers
  3. 9.3 Epistaxis Industry Opportunities and Challenges
  4. 9.4 Epistaxis Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst